secwatch.observer — SEC 8-K summary
======================================

Issuer:     NRX Pharmaceuticals, Inc. (NRXP)
CIK:        0001719406
Form:       8-K
Filed at:   2023-09-14T23:59:59+00:00
Accession:  0001104659-23-100780
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NRx names Richard Narido interim CFO; Seth Van Voorhees resigns Sept 30
-----------------------------------------------------------------------

- Seth Van Voorhees resigned as CFO effective Sept 30, 2023, no disagreement cited.
- Richard Narido appointed interim CFO effective Sept 13, 2023, via LifeSci Advisors consulting agreement.
- Narido previously CFO of Lucira Health until Pfizer acquisition in April 2023.
- LifeSci Agreement term is two years; includes non-competition/non-solicitation and placement fee provisions.
- Agreement prohibits solicitation of LifeSci-introduced professionals for one year, with 15% placement fee.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1719406/000110465923100780/0001104659-23-100780-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1719406/000110465923100780/tm2317653d13_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-100780

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer